Your Source for Venture Capital and Private Equity Financings

Evergreen Theragnostics Nets $15M Series B

2023-03-13
SPRINGFIELD, NJ, Evergreen Theragnostics, a clinical stage contract development and manufacturing organization, announced the completion of a $15M Series B.
Evergreen Theragnostics, a clinical stage contract development and manufacturing organization (CDMO) developing radiopharmaceuticals for cancer therapy, announced the completion of a $15M Series B capital raise. The round was primarily subscribed by existing shareholders exercising their rights of first refusal.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors